產品詳情
簡單介紹：
重組人骨形態發生蛋白2蛋白與其它公司提供的重組蛋白不同，rHuBMP-2蛋白產品為采用CFS的無細胞麥胚蛋白合成系統表達出來的重組蛋白，可表達出對細胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時獨有的全自動蛋白純化技術則簡便高效，將蛋白純化過程中對蛋白的損傷降低到*小程度.重組人骨形態發生蛋白2蛋白（全長序列）產品可用于Western Blot驗證、抗體制備、蛋白檢測、ELISA等試驗中.
詳情介紹：
重組人骨形態發生蛋白2蛋白
| Synonyms | BMP-2A |
| Species | Human |
| Accession | P12643 |
| GeneID | 650 |
| Source | Escherichia coli. |
| Molecular Weight | 重組人骨形態發生蛋白2蛋白Approximately 26.0 kDa, a homodimeric protein consisting of two 115 amino acid non-glycosylated polypeptide chains. |
| Quantity | 2μg/10μg/1000μg |
| AA Sequence | MQAKHKQRKR LKSSCKRHPL YVDFSDVGWN DWIVAPPGYH AFYCHGECPF PLADHLNSTN HAIVQTLVNS VNSKIPKACC VPTELSAISM LYLDENEKVV LKNYQDMVVE GCGCR |
| Purity | > 95 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人骨形態發生蛋白2蛋白Fully biologically active when compared to standard. The ED50 as determined by inducing alkaline phosphatase production of murine ATDC5 cells is less than 200 ng/ml, corresponding to a specific activity of > 5.0 × 103 IU/mg. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution containing 10 mM sodium citrate pH 3.5. |
| Endotoxin | Less than 1 EU/μg of rHuBMP-2 as determined by LAL method. |
| Reconstitution | 重組人骨形態發生蛋白2蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled H2O to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. Do not reconstitute in PBS or cell culture media. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人骨形態發生蛋白2蛋白 | |
| SDS-PAGE |
|
| Reference |
1. Chung YI, Ahn KM, Jeon SH, et al. 2007. J Control Release, 121: 91-9. 2. Yamaji K, Kawanami M, Matsumoto A, et al. 2007. Dent Mater J, 26: 481-6. 3. Allen RT, Lee YP, Stimson E, et al. 2007. Spine (Phila Pa 1976), 32: 2996-3006. 4. Shen B, Wei A, Tao H, et al. 2009. Tissue Eng Part A, 15: 1311-20. 5. Seib FP, Lanfer B, Bornhauser M, et al. 2010. J Tissue Eng Regen Med, 4: 324-7. 6. Itoh T, Ando M, Tsukamasa Y, et al. 2012. FEBS Lett, 586: 1693-701. |
| Background | Bone Morphogenetic Protein 2 is one of the BMPs, some of which belong to the TGF-beta superfamily (BMP2-7). There are more than thirteen BMPs have been discovered nowadays and they are involved in inducing cartilage and bone formation. BMP-2 is expressed in a variety of tissues including lung, spleen, brain, liver, prostate ovary and small intestine. It is a potent osteoinductive cytokine and plays its role in association with osteoconductive carriers such as collagen and synthetic hydroxyapatite. As it shown to stimulate the production of bone, the recombinant human BMP-2 is available for orthopaedic usage and dentisty. The functional form of BMP-2 is a disulflde-linked homodimer and about 26 kDa The precursor of BMP-2 is 259 a.a., containing the 23 a.a. N-terminal signal sequence which will be cleaved by a furin-type protease to form the mature peptide. |
